首页 > 最新文献

European urology oncology最新文献

英文 中文
Re: Guillaume Ploussard, Eric Barret, Gaëlle Fiard, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.01.019. Re:Guillaume Ploussard、Eric Barret、Gaëlle Fiard 等:经会阴与经直肠磁共振成像靶向活检诊断前列腺癌:随机 PERFECT 试验 (CCAFU-PR1) 的最终结果。欧洲泌尿肿瘤杂志》。https://doi.org/10.1016/j.euo.2024.01.019.
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-20 DOI: 10.1016/j.euo.2024.05.002
Fu-Xiang Lin, Yi Yu, Zhan-Ping Xu
{"title":"Re: Guillaume Ploussard, Eric Barret, Gaëlle Fiard, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.01.019.","authors":"Fu-Xiang Lin, Yi Yu, Zhan-Ping Xu","doi":"10.1016/j.euo.2024.05.002","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.002","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Validation of a Survey to Assess Sexual Health in Female Partners of Patients with Prostate Cancer. 前列腺癌患者女性伴侣性健康评估调查的开发与验证。
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-17 DOI: 10.1016/j.euo.2024.04.022
Stacy Loeb, Natasha Gupta, Daniela Wittmann, Christian J Nelson, John P Mulhall, Carolyn A Salter, Nataliya Byrne, Tatiana Sanchez Nolasco, Laura Zebib, Leigh Garrett, Elizabeth Schofield

Background: Prostate cancer (PCa) diagnosis and treatment can have a significant negative impact on sexual health, affecting patients and their partners; however, the impact on partners is insufficiently addressed in current practice.

Objective: We describe the development and validation of an instrument to measure sexual health in female partners of patients with PCa.

Design, setting, and participants: Questions assessing sexual health were developed through a literature review, two qualitative studies, and an expert consensus process. Candidate survey items were tested through cognitive interviews and used to iteratively refine the questionnaire.

Intervention: The final questionnaire was tested in a validation study among 200 female partners.

Outcome measurements and statistical analysis: We performed an exploratory factor analysis, followed by an analysis for internal validity, test-retest reliability, and convergent and discriminant validity.

Results and limitations: An initial set of 32 items was developed and refined through cognitive interviews. The resulting 27-item questionnaire was tested among 200 female partners of patients with PCa from across the USA. The exploratory factor analysis eliminated eight items and revealed seven key factors: (1) distress/satisfaction, (2) loss of connection as a couple, (3) active communication, (4) discomfort with communication, (5) frustration with sexual counseling, (6) expansion of sexual repertoire, and (7) nonpenetrative sexual activity. The overall scale demonstrated strong internal consistency (ordinal alpha 0.94) and test-retest reliability (0.89). Strengths of the study include development and evaluation of the first questionnaire to evaluate sexual quality of life among female partners of patients with PCa. However, additional work is needed to assess sexual health and quality of life among male and nonbinary partners.

Conclusions: We developed a new instrument, the Sexual Concerns In Partners of Patients with Prostate cancer (SCIPPP-F), and found it to be valid in a diverse sample of female partners across the USA.

Patient summary: Our new instrument can be used to characterize sexual health among female partners of patients with prostate cancer.

背景:前列腺癌(PCa)的诊断和治疗会对患者及其伴侣的性健康产生严重的负面影响;然而,在目前的实践中,对伴侣的影响还没有得到充分解决:我们介绍了一种用于测量 PCa 患者女性伴侣性健康的工具的开发和验证情况:通过文献综述、两项定性研究和专家共识程序,开发了评估性健康的问题。候选调查项目通过认知访谈进行测试,并用于反复完善问卷:最终问卷在 200 名女性伴侣中进行了验证研究:我们进行了探索性因素分析,然后分析了内部有效性、测试-再测试可靠性、收敛有效性和区分有效性:通过认知访谈,我们开发并完善了最初的 32 个项目。在全美 200 名 PCa 患者的女性伴侣中测试了最终形成的 27 个项目的问卷。探索性因子分析剔除了 8 个项目,发现了 7 个关键因子:(1) 痛苦/满意;(2) 失去夫妻间的联系;(3) 积极沟通;(4) 沟通不适;(5) 性咨询的挫折感;(6) 性活动范围的扩大;(7) 非开放性的性活动。整个量表显示出很强的内部一致性(序数α 0.94)和测试再测可靠性(0.89)。该研究的优点包括开发和评估了第一份评估 PCa 患者女性伴侣性生活质量的问卷。然而,还需要做更多的工作来评估男性和非二元性伴侣的性健康和生活质量:我们开发了一种新的工具--前列腺癌患者伴侣性关注(SCIPPP-F),并发现它在美国各地不同的女性伴侣样本中是有效的。患者总结:我们的新工具可用于描述前列腺癌患者女性伴侣的性健康特征。
{"title":"Development and Validation of a Survey to Assess Sexual Health in Female Partners of Patients with Prostate Cancer.","authors":"Stacy Loeb, Natasha Gupta, Daniela Wittmann, Christian J Nelson, John P Mulhall, Carolyn A Salter, Nataliya Byrne, Tatiana Sanchez Nolasco, Laura Zebib, Leigh Garrett, Elizabeth Schofield","doi":"10.1016/j.euo.2024.04.022","DOIUrl":"https://doi.org/10.1016/j.euo.2024.04.022","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) diagnosis and treatment can have a significant negative impact on sexual health, affecting patients and their partners; however, the impact on partners is insufficiently addressed in current practice.</p><p><strong>Objective: </strong>We describe the development and validation of an instrument to measure sexual health in female partners of patients with PCa.</p><p><strong>Design, setting, and participants: </strong>Questions assessing sexual health were developed through a literature review, two qualitative studies, and an expert consensus process. Candidate survey items were tested through cognitive interviews and used to iteratively refine the questionnaire.</p><p><strong>Intervention: </strong>The final questionnaire was tested in a validation study among 200 female partners.</p><p><strong>Outcome measurements and statistical analysis: </strong>We performed an exploratory factor analysis, followed by an analysis for internal validity, test-retest reliability, and convergent and discriminant validity.</p><p><strong>Results and limitations: </strong>An initial set of 32 items was developed and refined through cognitive interviews. The resulting 27-item questionnaire was tested among 200 female partners of patients with PCa from across the USA. The exploratory factor analysis eliminated eight items and revealed seven key factors: (1) distress/satisfaction, (2) loss of connection as a couple, (3) active communication, (4) discomfort with communication, (5) frustration with sexual counseling, (6) expansion of sexual repertoire, and (7) nonpenetrative sexual activity. The overall scale demonstrated strong internal consistency (ordinal alpha 0.94) and test-retest reliability (0.89). Strengths of the study include development and evaluation of the first questionnaire to evaluate sexual quality of life among female partners of patients with PCa. However, additional work is needed to assess sexual health and quality of life among male and nonbinary partners.</p><p><strong>Conclusions: </strong>We developed a new instrument, the Sexual Concerns In Partners of Patients with Prostate cancer (SCIPPP-F), and found it to be valid in a diverse sample of female partners across the USA.</p><p><strong>Patient summary: </strong>Our new instrument can be used to characterize sexual health among female partners of patients with prostate cancer.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer. 肌肉浸润性膀胱癌患者术前使用 Tislelizumab 联合低剂量纳布-紫杉醇的 2 期研究
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-17 DOI: 10.1016/j.euo.2024.04.020
Zhouliang Wu, Gangjian Zhao, Zhe Zhang, Chong Shen, Lili Wang, Guoping Xu, Yang Zhao, Rui Liang, Changping Li, Huanhuan Liu, Hongmei Wang, Hua Dong, Huaying Fu, Man Li, Hongjun Li, Yan Zhuang, La Da, Shiwang Huang, Kaipeng Jia, Houyuan Chen, Yiduo Bai, Shizheng Guo, Huanqing Cheng, Huina Wang, Haitao Wang, Yuanjie Niu, Hailong Hu

Background and objective: Combinations of immune checkpoint inhibitors and nab-paclitaxel have achieved significant therapeutic effects in the treatment of advanced urothelial carcinoma. Our aim was to assess the efficacy and safety of tislelizumab combined with low-dose nab-paclitaxel in patients with muscle-invasive bladder cancer (MIBC).

Methods: TRUCE-01 was a single-arm phase 2 study that included 62 patients with T2-4a N0/X M0 MIBC tumors with predominant urothelial carcinoma histology. Eligible patients received three 21-d cycles of intravenous 200 mg tislelizumab on day 1 plus intravenous 200 mg nab-paclitaxel on day 2, followed by surgical assessment. The primary study endpoint was a clinical complete response (cCR). Treatment-related adverse event (TRAE) profiles were recorded according to Common Terminology Criteria for Adverse Events version 5.0.

Key findings and limitations: The safety analysis included all 62 patients and the efficacy analysis included 48 patients. The primary efficacy endpoint (cCR) was met by 25 patients (52%) patients. Among the 62 patients in the safety analysis, six (9.7%) had grade ≥3 TRAEs.

Conclusions: Tislelizumab combined with low-dose nab-paclitaxel showed promising antitumor effectiveness and was generally well tolerated, which makes it an excellent preoperative therapy option for MIBC.

Patient summary: We found that a combination of the drugs tislelizumab and low-dose nab-paclitaxel had satisfactory efficacy and safety for preoperative treatment of muscle-invasive bladder cancer.

背景和目的:免疫检查点抑制剂与纳布-紫杉醇联合治疗晚期尿路上皮癌取得了显著疗效。我们的目的是评估tislelizumab联合小剂量纳布-紫杉醇治疗肌层浸润性膀胱癌(MIBC)患者的疗效和安全性:TRUCE-01是一项单臂2期研究,共纳入62例T2-4a N0/X M0 MIBC肿瘤患者,组织学以尿路上皮癌为主。符合条件的患者在第1天静脉注射200毫克替斯利珠单抗,第2天静脉注射200毫克纳布-紫杉醇,共接受3个21天周期的治疗,然后进行手术评估。主要研究终点是临床完全应答(cCR)。治疗相关不良事件(TRAE)情况根据不良事件通用术语标准5.0版进行记录:安全性分析包括所有 62 名患者,疗效分析包括 48 名患者。25名患者(52%)达到了主要疗效终点(cCR)。在安全性分析的62名患者中,有6名患者(9.7%)的TRAE≥3级:Tislelizumab联合小剂量纳布-紫杉醇显示出良好的抗肿瘤效果,且耐受性普遍良好,是治疗肌浸润性膀胱癌的绝佳术前治疗方案。患者总结:我们发现,tislelizumab和小剂量纳布-紫杉醇联合用于肌浸润性膀胱癌的术前治疗具有令人满意的疗效和安全性。
{"title":"Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer.","authors":"Zhouliang Wu, Gangjian Zhao, Zhe Zhang, Chong Shen, Lili Wang, Guoping Xu, Yang Zhao, Rui Liang, Changping Li, Huanhuan Liu, Hongmei Wang, Hua Dong, Huaying Fu, Man Li, Hongjun Li, Yan Zhuang, La Da, Shiwang Huang, Kaipeng Jia, Houyuan Chen, Yiduo Bai, Shizheng Guo, Huanqing Cheng, Huina Wang, Haitao Wang, Yuanjie Niu, Hailong Hu","doi":"10.1016/j.euo.2024.04.020","DOIUrl":"https://doi.org/10.1016/j.euo.2024.04.020","url":null,"abstract":"<p><strong>Background and objective: </strong>Combinations of immune checkpoint inhibitors and nab-paclitaxel have achieved significant therapeutic effects in the treatment of advanced urothelial carcinoma. Our aim was to assess the efficacy and safety of tislelizumab combined with low-dose nab-paclitaxel in patients with muscle-invasive bladder cancer (MIBC).</p><p><strong>Methods: </strong>TRUCE-01 was a single-arm phase 2 study that included 62 patients with T2-4a N0/X M0 MIBC tumors with predominant urothelial carcinoma histology. Eligible patients received three 21-d cycles of intravenous 200 mg tislelizumab on day 1 plus intravenous 200 mg nab-paclitaxel on day 2, followed by surgical assessment. The primary study endpoint was a clinical complete response (cCR). Treatment-related adverse event (TRAE) profiles were recorded according to Common Terminology Criteria for Adverse Events version 5.0.</p><p><strong>Key findings and limitations: </strong>The safety analysis included all 62 patients and the efficacy analysis included 48 patients. The primary efficacy endpoint (cCR) was met by 25 patients (52%) patients. Among the 62 patients in the safety analysis, six (9.7%) had grade ≥3 TRAEs.</p><p><strong>Conclusions: </strong>Tislelizumab combined with low-dose nab-paclitaxel showed promising antitumor effectiveness and was generally well tolerated, which makes it an excellent preoperative therapy option for MIBC.</p><p><strong>Patient summary: </strong>We found that a combination of the drugs tislelizumab and low-dose nab-paclitaxel had satisfactory efficacy and safety for preoperative treatment of muscle-invasive bladder cancer.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models. 与吉西他滨相比,氯法拉滨在膀胱癌临床前模型中具有更优越的治疗窗口期。
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-15 DOI: 10.1016/j.euo.2024.05.001
Michael Gutmann, Iris E Ertl, Paula Herek, Petra Vician, Christine Pirker, Christoph Nössing, Robert Brettner, Ursula Lemberger, Reinhard Grausenburger, Kai Batlogg, Oliver Baumfried, Isabella Prantl, Neha Singh, Ekaterina Laukhtina, André Oszwald, Gabriel Wasinger, Eva Compérat, Walter Berger, Shahrokh F Shariat, Bernhard Englinger

Current standard-of-care systemic therapy options for locally advanced and metastatic bladder cancer (BC), which are predominantly based on cisplatin-gemcitabine combinations, are limited by significant treatment failure rates and frailty-based patient ineligibility. We previously addressed the urgent clinical need for better-tolerated BC therapeutic strategies using a drug screening approach, which identified outstanding antineoplastic activity of clofarabine in preclinical models of BC. To further assess clofarabine as a potential BC therapy component, we conducted head-to-head comparisons of responses to clofarabine versus gemcitabine in preclinical in vitro and in vivo models of BC, complemented by in silico analyses. In vitro data suggest a distinct correlation between the two antimetabolites, with higher cytotoxicity of gemcitabine, especially against several nonmalignant cell types, including keratinocytes and endothelial cells. Accordingly, tolerance of clofarabine (oral or intraperitoneal application) was distinctly better than for gemcitabine (intraperitoneal) in patient-derived xenograft models of BC. Clofarabine also exhibited distinctly superior anticancer efficacy, even at dosing regimens optimized for gemcitabine. Neither complete remission nor cure, both of which were observed with clofarabine, were achieved with any tolerable gemcitabine regimen. Taken together, our findings demonstrate that clofarabine has a better therapeutic window than gemcitabine, further emphasizing its potential as a candidate for drug repurposing in BC. PATIENT SUMMARY: We compared the anticancer activity of clofarabine, a drug used for treatment of leukemia but not bladder cancer, and gemcitabine, a drug currently used for chemotherapy against bladder cancer. Using cell cultures and mouse models, we found that clofarabine was better tolerated and more efficacious than gemcitabine, and even cured implanted tumors in mouse models. Our results suggest that clofarabine, alone or in combination schemes, might be superior to gemcitabine for the treatment of bladder cancer.

目前治疗局部晚期和转移性膀胱癌(BC)的标准系统疗法主要以顺铂-吉西他滨联合疗法为主,但由于治疗失败率高和患者体质虚弱而不符合治疗条件,这种疗法受到了限制。此前,我们利用药物筛选方法解决了临床对耐受性更好的巴比妥类药物治疗策略的迫切需求,并在巴比妥类药物临床前模型中发现了氯法拉滨出色的抗肿瘤活性。为了进一步评估氯法拉滨作为一种潜在的BC治疗成分,我们在BC临床前体外和体内模型中对氯法拉滨和吉西他滨的反应进行了正面比较,并辅以硅学分析。体外数据表明,这两种抗代谢药物之间存在明显的相关性,吉西他滨的细胞毒性更高,尤其是针对几种非恶性细胞类型,包括角质形成细胞和内皮细胞。因此,在 BC 患者衍生异种移植模型中,氯法拉滨(口服或腹腔注射)的耐受性明显优于吉西他滨(腹腔注射)。氯法拉滨的抗癌疗效也明显优于吉西他滨,即使在吉西他滨的优化剂量方案中也是如此。在任何可耐受的吉西他滨治疗方案中,氯法拉滨都无法实现完全缓解或治愈。综上所述,我们的研究结果表明,氯法拉滨比吉西他滨具有更好的治疗窗口期,进一步凸显了其作为治疗 BC 的候选药物的潜力。患者摘要:我们比较了氯法拉滨和吉西他滨的抗癌活性,氯法拉滨是一种用于治疗白血病但不用于治疗膀胱癌的药物,而吉西他滨是一种目前用于化疗膀胱癌的药物。通过使用细胞培养物和小鼠模型,我们发现氯法拉滨比吉西他滨更耐受、更有效,甚至能治愈小鼠模型中的植入性肿瘤。我们的研究结果表明,在治疗膀胱癌方面,单独使用或联合使用氯法拉滨可能优于吉西他滨。
{"title":"Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models.","authors":"Michael Gutmann, Iris E Ertl, Paula Herek, Petra Vician, Christine Pirker, Christoph Nössing, Robert Brettner, Ursula Lemberger, Reinhard Grausenburger, Kai Batlogg, Oliver Baumfried, Isabella Prantl, Neha Singh, Ekaterina Laukhtina, André Oszwald, Gabriel Wasinger, Eva Compérat, Walter Berger, Shahrokh F Shariat, Bernhard Englinger","doi":"10.1016/j.euo.2024.05.001","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.001","url":null,"abstract":"<p><p>Current standard-of-care systemic therapy options for locally advanced and metastatic bladder cancer (BC), which are predominantly based on cisplatin-gemcitabine combinations, are limited by significant treatment failure rates and frailty-based patient ineligibility. We previously addressed the urgent clinical need for better-tolerated BC therapeutic strategies using a drug screening approach, which identified outstanding antineoplastic activity of clofarabine in preclinical models of BC. To further assess clofarabine as a potential BC therapy component, we conducted head-to-head comparisons of responses to clofarabine versus gemcitabine in preclinical in vitro and in vivo models of BC, complemented by in silico analyses. In vitro data suggest a distinct correlation between the two antimetabolites, with higher cytotoxicity of gemcitabine, especially against several nonmalignant cell types, including keratinocytes and endothelial cells. Accordingly, tolerance of clofarabine (oral or intraperitoneal application) was distinctly better than for gemcitabine (intraperitoneal) in patient-derived xenograft models of BC. Clofarabine also exhibited distinctly superior anticancer efficacy, even at dosing regimens optimized for gemcitabine. Neither complete remission nor cure, both of which were observed with clofarabine, were achieved with any tolerable gemcitabine regimen. Taken together, our findings demonstrate that clofarabine has a better therapeutic window than gemcitabine, further emphasizing its potential as a candidate for drug repurposing in BC. PATIENT SUMMARY: We compared the anticancer activity of clofarabine, a drug used for treatment of leukemia but not bladder cancer, and gemcitabine, a drug currently used for chemotherapy against bladder cancer. Using cell cultures and mouse models, we found that clofarabine was better tolerated and more efficacious than gemcitabine, and even cured implanted tumors in mouse models. Our results suggest that clofarabine, alone or in combination schemes, might be superior to gemcitabine for the treatment of bladder cancer.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. 短期达罗鲁胺(ODM-201)与放疗同时用于中危前列腺癌患者:Darius(AFU-GETUG P15)2期试验方案。
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-15 DOI: 10.1016/j.euo.2024.04.023
Paul Sargos, Carine Bellera, Rita Bentahila, Marie Guerni, Nicolas Benziane-Ouaritini, Diego Teyssonneau, Nam-Son Vuong, Guillaume Ploussard, Morgan Roupret, Guilhem Roubaud

Background: Combination of androgen deprivation therapy (ADT) with external beam radiation therapy (EBRT) is a standard of care for patients with intermediate-risk prostate cancer (PCa). However, 6 months of ADT generates multiple side effects impacting quality of life (QoL). Darolutamide (an androgen receptor targeting agent [ARTA]) is associated with low blood-brain barrier penetrance and less drug-drug interaction.

Objective: To assess the efficacy of a combination of 6 months of darolutamide with EBRT to treat patients with unfavorable intermediate-risk PCa.

Design, setting, and participants: The DARIUS trial is a multicenter randomized non comparative phase 2 trial, randomizing the 6-months darolutamide + EBRT arm versus 6-months ADT + EBRT in patients with unfavorable intermediate-risk PCa.

Outcome measurements and statistical analysis: The primary endpoint is a biological response defined as prostate-specific antigen ≤0.1 ng/ml at month six of darolutamide or ADT. The key secondary endpoints are biochemical recurrence-free survival, disease-free survival, safety, and QoL. Ancillary studies using radiomics and genomic classifier are planned. Sixty-two patients will be included.

Results and limitations: In this population of patients requiring ADT combined with EBRT, the use of an ARTA alone, such as darolutamide, may demonstrate antitumoral efficacy while minimizing toxicity and maintaining QoL. Limitations are mainly inherent to the open-label design of this study.

Conclusions: Six months of darolutamide + EBRT compared with 6 months of ADT + EBRT may be efficient in terms of a biological response, avoiding toxicity and altered QoL attributable to ADT in patients with unfavorable intermediate-risk PCa.

Patient summary: The ongoing DARIUS clinical trial assesses short-term (6 months) darolutamide treatment in association with external beam radiation therapy in men with localized prostate cancer. The trial investigates whether single-agent darolutamide can improve the biological response while maintaining a favorable tolerability profile.

背景:雄激素剥夺疗法(ADT)与体外放射治疗(EBRT)相结合是中危前列腺癌(PCa)患者的标准治疗方法。然而,6 个月的 ADT 会产生多种副作用,影响生活质量(QoL)。达罗他胺(雄激素受体靶向药[ARTA])的血脑屏障穿透性低,药物间相互作用少:目的:评估6个月达罗鲁胺联合EBRT治疗不利中危PCa患者的疗效:DARIUS试验是一项多中心随机非比较性2期试验,在不利中危PCa患者中随机分组6个月达罗鲁胺+EBRT与6个月ADT+EBRT:主要终点是生物反应,即服用达罗鲁胺或ADT第6个月时前列腺特异性抗原≤0.1 ng/ml。主要次要终点是无生化复发生存期、无疾病生存期、安全性和 QoL。计划使用放射组学和基因组分类器进行辅助研究。将纳入 62 名患者:在需要ADT联合EBRT的患者中,单独使用ARTA(如达洛他胺)可能会显示出抗肿瘤疗效,同时将毒性降至最低并保持QoL。本研究的局限性主要在于其开放标签设计:患者摘要:正在进行的 DARIUS 临床试验评估了达罗鲁胺短期(6 个月)治疗与局部前列腺癌男性患者体外放射治疗的结合情况。该试验研究单药达罗鲁胺是否能改善生物反应,同时保持良好的耐受性。
{"title":"Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol.","authors":"Paul Sargos, Carine Bellera, Rita Bentahila, Marie Guerni, Nicolas Benziane-Ouaritini, Diego Teyssonneau, Nam-Son Vuong, Guillaume Ploussard, Morgan Roupret, Guilhem Roubaud","doi":"10.1016/j.euo.2024.04.023","DOIUrl":"https://doi.org/10.1016/j.euo.2024.04.023","url":null,"abstract":"<p><strong>Background: </strong>Combination of androgen deprivation therapy (ADT) with external beam radiation therapy (EBRT) is a standard of care for patients with intermediate-risk prostate cancer (PCa). However, 6 months of ADT generates multiple side effects impacting quality of life (QoL). Darolutamide (an androgen receptor targeting agent [ARTA]) is associated with low blood-brain barrier penetrance and less drug-drug interaction.</p><p><strong>Objective: </strong>To assess the efficacy of a combination of 6 months of darolutamide with EBRT to treat patients with unfavorable intermediate-risk PCa.</p><p><strong>Design, setting, and participants: </strong>The DARIUS trial is a multicenter randomized non comparative phase 2 trial, randomizing the 6-months darolutamide + EBRT arm versus 6-months ADT + EBRT in patients with unfavorable intermediate-risk PCa.</p><p><strong>Outcome measurements and statistical analysis: </strong>The primary endpoint is a biological response defined as prostate-specific antigen ≤0.1 ng/ml at month six of darolutamide or ADT. The key secondary endpoints are biochemical recurrence-free survival, disease-free survival, safety, and QoL. Ancillary studies using radiomics and genomic classifier are planned. Sixty-two patients will be included.</p><p><strong>Results and limitations: </strong>In this population of patients requiring ADT combined with EBRT, the use of an ARTA alone, such as darolutamide, may demonstrate antitumoral efficacy while minimizing toxicity and maintaining QoL. Limitations are mainly inherent to the open-label design of this study.</p><p><strong>Conclusions: </strong>Six months of darolutamide + EBRT compared with 6 months of ADT + EBRT may be efficient in terms of a biological response, avoiding toxicity and altered QoL attributable to ADT in patients with unfavorable intermediate-risk PCa.</p><p><strong>Patient summary: </strong>The ongoing DARIUS clinical trial assesses short-term (6 months) darolutamide treatment in association with external beam radiation therapy in men with localized prostate cancer. The trial investigates whether single-agent darolutamide can improve the biological response while maintaining a favorable tolerability profile.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional Outcomes and Quality of Life in High-risk Prostate Cancer Patients Treated by Robot-assisted Radical Prostatectomy with or Without Adjuvant Treatments. 接受或不接受辅助治疗的机器人辅助根治性前列腺切除术的高危前列腺癌患者的功能结果和生活质量
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-15 DOI: 10.1016/j.euo.2024.04.018
Wout Devlies, Geert Silversmit, Filip Ameye, Peter Dekuyper, Thierry Quackels, Thierry Roumeguère, Ben Van Cleynenbreugel, Nancy Van Damme, Frank Claessens, Wouter Everaerts, Steven Joniau

Background: Robot-assisted laparoscopic prostatectomy (RALP) is used frequently to treat prostate cancer; yet, prospective data on the quality of life and functional outcomes are lacking.

Objective: To assess the quality of life and functional outcomes after radical prostatectomy in different risk groups with or without adjuvant treatments.

Design, setting, and participants: The Be-RALP database is a prospective multicentre database that covers 9235 RALP cases from 2009 until 2016. Of these 9235 patients, 2336 high-risk prostate cancer patients were matched with low/intermediate-risk prostate cancer patients.

Intervention: Patients were treated with RALP only or followed by radiotherapy and/or hormone treatment.

Outcome measurements and statistical analysis: We used a mixed-model analysis to longitudinally analyse quality of life, urinary function, and erectile function between risk groups with or without additional treatments.

Results and limitations: Risk group was not significant in predicting quality of life, erectile function, or urinary function after RALP. Postoperative treatment (hormone and/or radiotherapy treatment) was significant in predicting International Index of Erectile Function (IIEF-5), sexual activity, and sexual functioning.

Conclusions: Risk group was not linked with clinically relevant declines in functional outcomes after RALP. The observed functional outcomes and quality of life are in favour of considering RALP for high-risk prostate cancer. Postoperative treatment resulted in lower erectile function measures without clinically relevant changes in quality of life and urinary functions. Hormone therapy seems to have the most prominent negative effects on these outcomes.

Patient summary: This study investigated the quality of life, and urinary and erectile function in patients with aggressive and less aggressive prostate cancer after surgery only or in combination with hormones or radiation. We found that quality of life recovers completely, while erectile and urinary function recovers only partially after surgery. Aggressiveness of the disease had a minimal effect on the outcomes; yet, postoperative treatments lowered erectile function further.

背景:机器人辅助腹腔镜前列腺切除术(RALP机器人辅助腹腔镜前列腺切除术(RALP)被频繁用于治疗前列腺癌;然而,有关生活质量和功能预后的前瞻性数据却缺乏:目的:评估不同风险人群在接受或未接受辅助治疗的情况下接受根治性前列腺切除术后的生活质量和功能预后:Be-RALP数据库是一个前瞻性多中心数据库,涵盖2009年至2016年的9235例RALP病例。在这9235例患者中,2336例高风险前列腺癌患者与低/中风险前列腺癌患者进行了配对:结果测量和统计分析:我们采用混合模型分析法,纵向分析了接受或不接受额外治疗的风险组之间的生活质量、泌尿功能和勃起功能:风险组别对 RALP 术后生活质量、勃起功能或排尿功能的预测意义不大。术后治疗(激素和/或放疗治疗)对预测国际勃起功能指数(IIEF-5)、性活动和性功能有显著影响:结论:风险组别与 RALP 术后临床相关的功能结果下降无关。观察到的功能结果和生活质量支持考虑对高风险前列腺癌患者进行 RALP 治疗。术后治疗导致勃起功能降低,但生活质量和泌尿功能没有发生临床相关变化。患者总结:这项研究调查了侵袭性和侵袭性较低的前列腺癌患者在仅接受手术或结合激素或放射治疗后的生活质量、泌尿和勃起功能。我们发现,手术后生活质量完全恢复,而勃起和排尿功能仅部分恢复。疾病的侵袭性对结果的影响微乎其微;然而,术后治疗会进一步降低勃起功能。
{"title":"Functional Outcomes and Quality of Life in High-risk Prostate Cancer Patients Treated by Robot-assisted Radical Prostatectomy with or Without Adjuvant Treatments.","authors":"Wout Devlies, Geert Silversmit, Filip Ameye, Peter Dekuyper, Thierry Quackels, Thierry Roumeguère, Ben Van Cleynenbreugel, Nancy Van Damme, Frank Claessens, Wouter Everaerts, Steven Joniau","doi":"10.1016/j.euo.2024.04.018","DOIUrl":"https://doi.org/10.1016/j.euo.2024.04.018","url":null,"abstract":"<p><strong>Background: </strong>Robot-assisted laparoscopic prostatectomy (RALP) is used frequently to treat prostate cancer; yet, prospective data on the quality of life and functional outcomes are lacking.</p><p><strong>Objective: </strong>To assess the quality of life and functional outcomes after radical prostatectomy in different risk groups with or without adjuvant treatments.</p><p><strong>Design, setting, and participants: </strong>The Be-RALP database is a prospective multicentre database that covers 9235 RALP cases from 2009 until 2016. Of these 9235 patients, 2336 high-risk prostate cancer patients were matched with low/intermediate-risk prostate cancer patients.</p><p><strong>Intervention: </strong>Patients were treated with RALP only or followed by radiotherapy and/or hormone treatment.</p><p><strong>Outcome measurements and statistical analysis: </strong>We used a mixed-model analysis to longitudinally analyse quality of life, urinary function, and erectile function between risk groups with or without additional treatments.</p><p><strong>Results and limitations: </strong>Risk group was not significant in predicting quality of life, erectile function, or urinary function after RALP. Postoperative treatment (hormone and/or radiotherapy treatment) was significant in predicting International Index of Erectile Function (IIEF-5), sexual activity, and sexual functioning.</p><p><strong>Conclusions: </strong>Risk group was not linked with clinically relevant declines in functional outcomes after RALP. The observed functional outcomes and quality of life are in favour of considering RALP for high-risk prostate cancer. Postoperative treatment resulted in lower erectile function measures without clinically relevant changes in quality of life and urinary functions. Hormone therapy seems to have the most prominent negative effects on these outcomes.</p><p><strong>Patient summary: </strong>This study investigated the quality of life, and urinary and erectile function in patients with aggressive and less aggressive prostate cancer after surgery only or in combination with hormones or radiation. We found that quality of life recovers completely, while erectile and urinary function recovers only partially after surgery. Aggressiveness of the disease had a minimal effect on the outcomes; yet, postoperative treatments lowered erectile function further.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study. 雷替凡利单抗治疗晚期阴茎鳞状细胞癌:ORPHEUS 2 期研究
IF 8.3 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-14 DOI: 10.1016/j.euo.2024.04.021
Xavier García Del Muro, David Páez López-Bravo, Miler Andrés Cuéllar-Rivas, Pablo Maroto, Patrizia Giannatempo, Daniel Castellano, Miguel A Climent, Begoña P Valderrama, Alfonso Gómez de Liaño, Laura López-Montero, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo-Cordero, Andrea Necchi

Background and objective: Patients with advanced penile squamous cell carcinoma (PSCC) have poor outcomes and very limited therapeutic options are available. Most PSCC cases have high PD-L1 expression, which is associated with worse prognosis. Immunotherapy targeting PD-L1 could benefit patients with PSCC. Our aim was to evaluate the efficacy and safety of the anti-PD-1 antibody retifanlimab in patients with advanced/metastatic PSCC.

Methods: ORPHEUS was a single-arm, multicenter, phase 2 trial in 18 patients with advanced/metastatic PSCC, previously untreated with anti-PD-1/anti-PD-L1 agents. Patients received retifanlimab 500 mg intravenously every 4 wk for up to 2 yr. The primary endpoint was the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included the clinical benefit rate (CBR), disease control rate, duration of response (DoR), time to response, progression-free survival (PFS), overall survival (OS), maximum tumor shrinkage, and safety. The Wilson method was used for the primary endpoint, and the Clopper-Pearson and Kaplan-Meier methods for secondary endpoints.

Key findings and limitations: Median follow-up was 7.2 mo. The ORR was 16.7% (95% confidence interval [CI] 5.8-39.2); three patients had a partial response. Median DoR was 3.3 mo (range 1.8-8.5). The CBR was 22.2% (95% CI 6.4-47.6%). Median PFS was 2.0 mo (95% CI 1.6-3.3) and median OS was 7.2 mo (95% CI 3.0-9.8). One patient (5.6%) experienced grade 3 treatment-related adverse events (AEs). There were no grade >= 4 treatment-related AEs. The small sample size is the main limitation.

Conclusions and clinical implications: Single-agent retifanlimab exhibited signals of clinical activity in advanced/metastatic PSCC, with no new safety signals. Further investigation of retifanlimab in this setting is warranted.

Patient summary: Advanced penile cancer of the squamous cell type is a rare tumor with poor prognosis. The aggressiveness of this cancer is usually associated with high levels of a protein called PD-L1. We investigated whether retifanlimab, an immunotherapy drug against PD-1, has activity against this type of penile cancer. Tumor regression or stabilization occurred in one-third of the patients and the side effects were manageable.

背景和目的:晚期阴茎鳞状细胞癌(PSCC)患者的预后较差,可供选择的治疗方案非常有限。大多数阴茎鳞状细胞癌病例的PD-L1表达较高,这与预后较差有关。针对PD-L1的免疫疗法可使PSCC患者受益。我们的目的是评估抗PD-1抗体retifanlimab在晚期/转移性PSCC患者中的疗效和安全性:ORPHEUS是一项单臂、多中心、2期试验,18名晚期/转移性PSCC患者既往未接受过抗PD-1/抗PD-L1药物治疗。根据实体瘤反应评估标准 v1.1,主要终点是客观反应率(ORR)。次要终点包括临床获益率(CBR)、疾病控制率、反应持续时间(DoR)、反应时间、无进展生存期(PFS)、总生存期(OS)、最大肿瘤缩小率和安全性。主要终点采用 Wilson 方法,次要终点采用 Clopper-Pearson 和 Kaplan-Meier 方法:中位随访时间为7.2个月。ORR为16.7%(95%置信区间[CI] 5.8-39.2);3名患者出现部分反应。中位DoR为3.3个月(范围1.8-8.5)。CBR 为 22.2% (95% CI 6.4-47.6%)。中位 PFS 为 2.0 个月(95% CI 1.6-3.3),中位 OS 为 7.2 个月(95% CI 3.0-9.8)。一名患者(5.6%)出现了3级治疗相关不良事件(AE)。没有 >= 4 级的治疗相关不良事件。样本量小是主要的局限性:单药瑞替单抗在晚期/转移性PSCC中显示出临床活性信号,没有新的安全性信号。患者总结:晚期鳞状细胞型阴茎癌是一种罕见的肿瘤,预后较差。这种癌症的侵袭性通常与高水平的PD-L1蛋白有关。我们研究了针对PD-1的免疫疗法药物retifanlimab是否对这种类型的阴茎癌具有活性。三分之一的患者肿瘤消退或稳定,副作用可控。
{"title":"Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study.","authors":"Xavier García Del Muro, David Páez López-Bravo, Miler Andrés Cuéllar-Rivas, Pablo Maroto, Patrizia Giannatempo, Daniel Castellano, Miguel A Climent, Begoña P Valderrama, Alfonso Gómez de Liaño, Laura López-Montero, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo-Cordero, Andrea Necchi","doi":"10.1016/j.euo.2024.04.021","DOIUrl":"10.1016/j.euo.2024.04.021","url":null,"abstract":"<p><strong>Background and objective: </strong>Patients with advanced penile squamous cell carcinoma (PSCC) have poor outcomes and very limited therapeutic options are available. Most PSCC cases have high PD-L1 expression, which is associated with worse prognosis. Immunotherapy targeting PD-L1 could benefit patients with PSCC. Our aim was to evaluate the efficacy and safety of the anti-PD-1 antibody retifanlimab in patients with advanced/metastatic PSCC.</p><p><strong>Methods: </strong>ORPHEUS was a single-arm, multicenter, phase 2 trial in 18 patients with advanced/metastatic PSCC, previously untreated with anti-PD-1/anti-PD-L1 agents. Patients received retifanlimab 500 mg intravenously every 4 wk for up to 2 yr. The primary endpoint was the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included the clinical benefit rate (CBR), disease control rate, duration of response (DoR), time to response, progression-free survival (PFS), overall survival (OS), maximum tumor shrinkage, and safety. The Wilson method was used for the primary endpoint, and the Clopper-Pearson and Kaplan-Meier methods for secondary endpoints.</p><p><strong>Key findings and limitations: </strong>Median follow-up was 7.2 mo. The ORR was 16.7% (95% confidence interval [CI] 5.8-39.2); three patients had a partial response. Median DoR was 3.3 mo (range 1.8-8.5). The CBR was 22.2% (95% CI 6.4-47.6%). Median PFS was 2.0 mo (95% CI 1.6-3.3) and median OS was 7.2 mo (95% CI 3.0-9.8). One patient (5.6%) experienced grade 3 treatment-related adverse events (AEs). There were no grade >= 4 treatment-related AEs. The small sample size is the main limitation.</p><p><strong>Conclusions and clinical implications: </strong>Single-agent retifanlimab exhibited signals of clinical activity in advanced/metastatic PSCC, with no new safety signals. Further investigation of retifanlimab in this setting is warranted.</p><p><strong>Patient summary: </strong>Advanced penile cancer of the squamous cell type is a rare tumor with poor prognosis. The aggressiveness of this cancer is usually associated with high levels of a protein called PD-L1. We investigated whether retifanlimab, an immunotherapy drug against PD-1, has activity against this type of penile cancer. Tumor regression or stabilization occurred in one-third of the patients and the side effects were manageable.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.3,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review. 影响局部或局部晚期前列腺癌患者治疗决策和决策后悔的影响因素:系统性文献综述。
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-13 DOI: 10.1016/j.euo.2024.04.016
Benjamin A Gartrell, Angaja Phalguni, Paulina Bajko, Suneel D Mundle, Sharon A McCarthy, Sabine D Brookman-May, Francesco De Solda, Ruhee Jain, Wellam Yu Ko, Guillaume Ploussard, Boris Hadaschik

Context: Treatment decision-making (TDM) for patients with localized (LPC) or locally advanced (LAPC) prostate cancer is complex, and post-treatment decision regret (DR) is common. The factors driving TDM or predicting DR remain understudied.

Objective: Two systematic literature reviews were conducted to explore the factors associated with TDM and DR.

Evidence acquisition: Three online databases, select congress proceedings, and gray literature were searched (September 2022). Publications on TDM and DR in LPC/LAPC were prioritized based on the following: 2012 onward, ≥100 patients, journal article, and quantitative data. The Preferred Reporting Items Reviews and Meta-analyses guidelines were followed. Influential factors were those with p < 0.05; for TDM, factors described as "a decision driver", "associated", "influential", or "significant" were also included. The key factors were determined by number of studies, consistency of evidence, and study quality.

Evidence synthesis: Seventy-five publications (68 studies) reported TDM. Patient participation in TDM was reported in 34 publications; overall, patients preferred an active/shared role. Of 39 influential TDM factors, age, ethnicity, external factors (physician recommendation most common), and treatment characteristics/toxicity were key. Forty-nine publications reported DR. The proportion of patients experiencing DR varied by treatment type: 7-43% (active surveillance), 12-57% (radical prostatectomy), 1-49% (radiotherapy), 28-49% (androgen-deprivation therapy), and 21-47% (combination therapy). Of 42 significant DR factors, treatment toxicity (sexual/urinary/bowel dysfunction), patient role in TDM, and treatment type were key.

Conclusions: The key factors impacting TDM were physician recommendation, age, ethnicity, and treatment characteristics. Treatment toxicity and TDM approach were the key factors influencing DR. To help patients navigate factors influencing TDM and to limit DR, a shared, consensual TDM approach between patients, caregivers, and physicians is needed.

Patient summary: We looked at factors influencing treatment decision-making (TDM) and decision regret (DR) in patients with localized or locally advanced prostate cancer. The key factors influencing TDM were doctor's recommendation, patient age/ethnicity, and treatment side effects. A shared, consensual TDM approach between patients and doctors was found to limit DR.

背景:前列腺癌局部(LPC)或局部晚期(LAPC)患者的治疗决策(TDM)非常复杂,治疗后决策后悔(DR)也很常见。对推动 TDM 或预测 DR 的因素仍然研究不足:目的:我们进行了两项系统性文献综述,以探讨与TDM和DR相关的因素:检索了三个在线数据库、部分大会论文集和灰色文献(2022 年 9 月)。有关 LPC/LAPC 中 TDM 和 DR 的文献根据以下内容进行优先排序:2012年以后、≥100名患者、期刊论文和定量数据。研究遵循 "优选报告项目"(Preferred Reporting Items Reviews and Meta-analyses)指南。证据综述:75篇文献(68项研究)报道了TDM。有 34 篇文献报道了患者参与 TDM 的情况;总体而言,患者更倾向于主动/分担角色。在 39 个影响 TDM 的因素中,年龄、种族、外部因素(最常见的是医生建议)和治疗特点/毒性是关键因素。有 49 篇文献报道了 DR。出现 DR 的患者比例因治疗类型而异:7-43%(主动监测)、12-57%(根治性前列腺切除术)、1-49%(放疗)、28-49%(雄激素剥夺疗法)和 21-47%(综合疗法)。在42个重要的DR因素中,治疗毒性(性/泌尿/肠功能障碍)、患者在TDM中的角色以及治疗类型是关键因素:影响 TDM 的关键因素是医生建议、年龄、种族和治疗特点。治疗毒性和 TDM 方法是影响 DR 的关键因素。患者摘要:我们研究了影响局部或局部晚期前列腺癌患者治疗决策(TDM)和决策后悔(DR)的因素。影响 TDM 的关键因素是医生的建议、患者的年龄/种族和治疗副作用。研究发现,患者和医生之间共同认可的 TDM 方法可限制 DR。
{"title":"Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.","authors":"Benjamin A Gartrell, Angaja Phalguni, Paulina Bajko, Suneel D Mundle, Sharon A McCarthy, Sabine D Brookman-May, Francesco De Solda, Ruhee Jain, Wellam Yu Ko, Guillaume Ploussard, Boris Hadaschik","doi":"10.1016/j.euo.2024.04.016","DOIUrl":"https://doi.org/10.1016/j.euo.2024.04.016","url":null,"abstract":"<p><strong>Context: </strong>Treatment decision-making (TDM) for patients with localized (LPC) or locally advanced (LAPC) prostate cancer is complex, and post-treatment decision regret (DR) is common. The factors driving TDM or predicting DR remain understudied.</p><p><strong>Objective: </strong>Two systematic literature reviews were conducted to explore the factors associated with TDM and DR.</p><p><strong>Evidence acquisition: </strong>Three online databases, select congress proceedings, and gray literature were searched (September 2022). Publications on TDM and DR in LPC/LAPC were prioritized based on the following: 2012 onward, ≥100 patients, journal article, and quantitative data. The Preferred Reporting Items Reviews and Meta-analyses guidelines were followed. Influential factors were those with p < 0.05; for TDM, factors described as \"a decision driver\", \"associated\", \"influential\", or \"significant\" were also included. The key factors were determined by number of studies, consistency of evidence, and study quality.</p><p><strong>Evidence synthesis: </strong>Seventy-five publications (68 studies) reported TDM. Patient participation in TDM was reported in 34 publications; overall, patients preferred an active/shared role. Of 39 influential TDM factors, age, ethnicity, external factors (physician recommendation most common), and treatment characteristics/toxicity were key. Forty-nine publications reported DR. The proportion of patients experiencing DR varied by treatment type: 7-43% (active surveillance), 12-57% (radical prostatectomy), 1-49% (radiotherapy), 28-49% (androgen-deprivation therapy), and 21-47% (combination therapy). Of 42 significant DR factors, treatment toxicity (sexual/urinary/bowel dysfunction), patient role in TDM, and treatment type were key.</p><p><strong>Conclusions: </strong>The key factors impacting TDM were physician recommendation, age, ethnicity, and treatment characteristics. Treatment toxicity and TDM approach were the key factors influencing DR. To help patients navigate factors influencing TDM and to limit DR, a shared, consensual TDM approach between patients, caregivers, and physicians is needed.</p><p><strong>Patient summary: </strong>We looked at factors influencing treatment decision-making (TDM) and decision regret (DR) in patients with localized or locally advanced prostate cancer. The key factors influencing TDM were doctor's recommendation, patient age/ethnicity, and treatment side effects. A shared, consensual TDM approach between patients and doctors was found to limit DR.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140920673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy. 新发转移性阉割敏感性前列腺癌与局部治疗后转移复发的肿瘤基因表达谱差异。
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-11 DOI: 10.1016/j.euo.2024.04.013
Vinay Mathew Thomas, Nicolas Sayegh, Beverly Chigarira, Georges Gebrael, Nishita Tripathi, Roberto Nussenzveig, Yeonjung Jo, Emre Dal, Gliceida Galarza Fortuna, Haoran Li, Kamal Kant Sahu, Ayana Srivastava, Benjamin L Maughan, Neeraj Agarwal, Umang Swami

Background and objective: It has been reported that patients with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) have worse prognosis and outcomes than those whose cancer relapses after prior local therapy (PLT-mCSPC). Our aim was to interrogate and validate underlying differences in tumor gene expression profiles between dn-mCSPC and PLT-mCSPC.

Methods: The inclusion criteria were histologically confirmed prostate adenocarcinoma and the availability of RNA sequencing data for treatment-naïve primary prostate tissue. RNA sequencing was performed by Tempus or Caris Life Sciences, both of which have Clinical Laboratory Improvement Amendments certification. The Tempus cohort was used for interrogation, while the Caris cohort was used for validation. Differential gene expression analysis between the cohorts was conducted using the DEseq2 pipeline. The resulting gene expression profiles were further analyzed using Gene Set Enrichment software to identify pathways with enrichment in each cohort.

Key findings and limitations: Overall, 128 patients were eligible, of whom 78 were in the Tempus cohort (dn-mCSPC 37, PLT-mCSPC 41) and 50 were in the Caris cohort (dn-mCSPC 30, PLT-mCSPC 20). Tumor tissues from patients with dn-mCSPC had higher expression of genes associated with inflammation pathways, while tissues from patients with PLT-mCSPC had higher expression of genes involved in oxidative phosphorylation, fatty acid metabolism, and androgen response pathways.

Conclusions and clinical implications: Our study revealed upregulation of distinct genomic pathways in dn-mCSPC in comparison to PLT-mCSPC. These hypothesis-generating data could guide personalized therapy for men with prostate cancer and explain different survival outcomes for dn-mCSPC and PLT-mCSPC.

Patient summary: We measured gene expression levels in tumors from patients with metastatic castration-sensitive prostate cancer. In patients with metastatic disease at first diagnosis, inflammatory pathways were upregulated. In patients whose metastasis occurred on relapse after treatment, androgen response pathways were upregulated. These findings could help in personalizing therapy for prostate cancer and explaining differences in survival.

背景和目的:有报道称,新发转移性阉割敏感性前列腺癌(dn-mCSPC)患者的预后和疗效比那些经过局部治疗后复发的前列腺癌患者(PLT-mCSPC)差。我们的目的是研究并验证dn-mCSPC和PLT-mCSPC之间肿瘤基因表达谱的潜在差异:纳入标准:组织学确诊的前列腺腺癌和治疗无效的原发性前列腺组织的RNA测序数据。RNA测序由Tempus或Caris Life Sciences公司进行,这两家公司都获得了临床实验室改进修正案认证。Tempus队列用于询问,Caris队列用于验证。队列间的基因表达差异分析采用 DEseq2 管道进行。使用基因组富集软件对所得基因表达谱进行进一步分析,以确定每个队列中的富集通路:共有 128 例患者符合条件,其中 78 例属于 Tempus 队列(dn-mCSPC 37 例,PLT-mCSPC 41 例),50 例属于 Caris 队列(dn-mCSPC 30 例,PLT-mCSPC 20 例)。dn-mCSPC患者的肿瘤组织中与炎症通路相关的基因表达较高,而PLT-mCSPC患者的肿瘤组织中涉及氧化磷酸化、脂肪酸代谢和雄激素反应通路的基因表达较高:我们的研究揭示了与 PLT-mCSPC 相比,dn-mCSPC 中不同基因组通路的上调。这些假设性数据可指导男性前列腺癌患者的个性化治疗,并解释dn-mCSPC和PLT-mCSPC的不同生存结果。患者摘要:我们测量了转移性阉割敏感性前列腺癌患者肿瘤中的基因表达水平。在初诊时患有转移性疾病的患者中,炎症通路上调。在治疗后复发转移的患者中,雄激素反应通路上调。这些发现有助于对前列腺癌进行个性化治疗,并解释生存率的差异。
{"title":"Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy.","authors":"Vinay Mathew Thomas, Nicolas Sayegh, Beverly Chigarira, Georges Gebrael, Nishita Tripathi, Roberto Nussenzveig, Yeonjung Jo, Emre Dal, Gliceida Galarza Fortuna, Haoran Li, Kamal Kant Sahu, Ayana Srivastava, Benjamin L Maughan, Neeraj Agarwal, Umang Swami","doi":"10.1016/j.euo.2024.04.013","DOIUrl":"https://doi.org/10.1016/j.euo.2024.04.013","url":null,"abstract":"<p><strong>Background and objective: </strong>It has been reported that patients with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) have worse prognosis and outcomes than those whose cancer relapses after prior local therapy (PLT-mCSPC). Our aim was to interrogate and validate underlying differences in tumor gene expression profiles between dn-mCSPC and PLT-mCSPC.</p><p><strong>Methods: </strong>The inclusion criteria were histologically confirmed prostate adenocarcinoma and the availability of RNA sequencing data for treatment-naïve primary prostate tissue. RNA sequencing was performed by Tempus or Caris Life Sciences, both of which have Clinical Laboratory Improvement Amendments certification. The Tempus cohort was used for interrogation, while the Caris cohort was used for validation. Differential gene expression analysis between the cohorts was conducted using the DEseq2 pipeline. The resulting gene expression profiles were further analyzed using Gene Set Enrichment software to identify pathways with enrichment in each cohort.</p><p><strong>Key findings and limitations: </strong>Overall, 128 patients were eligible, of whom 78 were in the Tempus cohort (dn-mCSPC 37, PLT-mCSPC 41) and 50 were in the Caris cohort (dn-mCSPC 30, PLT-mCSPC 20). Tumor tissues from patients with dn-mCSPC had higher expression of genes associated with inflammation pathways, while tissues from patients with PLT-mCSPC had higher expression of genes involved in oxidative phosphorylation, fatty acid metabolism, and androgen response pathways.</p><p><strong>Conclusions and clinical implications: </strong>Our study revealed upregulation of distinct genomic pathways in dn-mCSPC in comparison to PLT-mCSPC. These hypothesis-generating data could guide personalized therapy for men with prostate cancer and explain different survival outcomes for dn-mCSPC and PLT-mCSPC.</p><p><strong>Patient summary: </strong>We measured gene expression levels in tumors from patients with metastatic castration-sensitive prostate cancer. In patients with metastatic disease at first diagnosis, inflammatory pathways were upregulated. In patients whose metastasis occurred on relapse after treatment, androgen response pathways were upregulated. These findings could help in personalizing therapy for prostate cancer and explaining differences in survival.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial. 醋酸阿比特龙、前列腺床放疗和促黄体生成素释放激素激动剂联合治疗前列腺切除术后生化复发患者(CARLHA):2期临床试验。
IF 8.2 1区 医学 Q1 Medicine Pub Date : 2024-05-10 DOI: 10.1016/j.euo.2024.04.014
Loic Ah-Thiane, Loic Campion, Nedjla Allouache, Emmanuel Meyer, Pascal Pommier, Nathalie Mesgouez-Nebout, Anne-Agathe Serre, Gilles Créhange, Valentine Guimas, Emmanuel Rio, Paul Sargos, Sylvain Ladoire, Céline Mahier Ait Oukhatar, Stéphane Supiot

Background: The relevance of next-generation hormone therapies and circulating tumor cells (CTCs) are not elucidated in biochemical recurrence after prostatectomy.

Objective: To evaluate the combination of abiraterone acetate plus prednisone (AAP), prostate bed radiotherapy (PBRT), and goserelin in biochemically relapsing men after prostatectomy, and to investigate the utility of CTCs.

Design, setting, and participants: In this single-arm multicenter phase 2 trial, 46 biochemically relapsing men were enrolled between December 2012 and January 2019. The median follow-up was 47 mo.

Intervention: All patients received AAP 1000 mg daily (but 750 mg during PBRT), salvage PBRT, and goserelin.

Outcome measurements and statistical analysis: The primary outcome was 3-yr biochemical recurrence-free survival (bRFS) when prostate-specific antigen (PSA) levels were ≥0.2 ng/ml. The secondary outcomes included alternative bRFS (alt-bRFS) when PSA levels were ≥0.5 ng/ml and safety assessment. CTC count was assessed.

Results and limitations: The 3-yr bRFS and alt-bRFS were 81.5% (95% confidence interval or CI [66.4-90.3%]) and 95.6% (95% CI [83.5-98.9%]), respectively. The most common acute radiotherapy-related adverse effect (AE; all grades was pollakiuria (41.3%). The most common late AE (all grades) was urinary incontinence (15.2%). Grade 3-4 acute or late radiotherapy-related AEs were scarce. Most frequent AEs nonrelated to radiotherapy were hot flashes (76%), hypertension (63%), and hepatic cytolysis (50%, of which 20% were of grades 3-4). Of the patients, 11% had a CTC count of ≥5, which was correlated with poorer bRFS (p = 0.042) and alt-bRFS (p = 0.008). The association between CTC count and higher rates of relapse was independent of the baseline PSA level and PSA doubling time (p = 0.42 and p = 0.09, respectively). This study was nonrandomized with a limited number of patients, and few clinical events were reported.

Conclusions: Adding AAP to salvage radiation therapy and goserelin resulted in high bRFS and alt-bRFS. AEs remained manageable, although a close liver surveillance is advised. CTC count appears as a promising biomarker for prognosis and predicting response to treatment.

Patient summary: Our study was a phase 2 clinical trial that exhibited the efficacy and tolerance of a novel androgen-receptor targeting agent (abiraterone acetate plus prednisone) in patients with prostate cancer who experienced rising prostate-specific antigen after radical prostatectomy, in combination with prostate bed radiotherapy. The results also indicated the feasibility and potential value of circulating tumor cell detection, which constitutes a possible advance in managing prostate cancers.

背景:新一代激素疗法和循环肿瘤细胞(CTCs)与前列腺切除术后生化复发的相关性尚未阐明:新一代激素疗法和循环肿瘤细胞(CTC)与前列腺切除术后生化复发的相关性尚未阐明:评估醋酸阿比特龙加泼尼松(AAP)、前列腺床放疗(PBRT)和戈舍瑞林联合治疗前列腺切除术后生化复发男性的效果,并研究CTCs的效用:在这项单臂多中心 2 期试验中,2012 年 12 月至 2019 年 1 月间共招募了 46 名生化复发的男性患者。中位随访时间为47个月:所有患者每天接受AAP 1000毫克(但在PBRT期间为750毫克)、挽救性PBRT和戈舍瑞林治疗:主要结果是前列腺特异性抗原(PSA)水平≥0.2纳克/毫升时的3年无生化复发生存率(bRFS)。次要结果包括 PSA 水平≥0.5 纳克/毫升时的替代无生化复发生存率(alt-bRFS)和安全性评估。对CTC计数进行了评估:3年bRFS和alt-bRFS分别为81.5%(95%置信区间或CI [66.4-90.3%])和95.6%(95% CI [83.5-98.9%])。最常见的急性放疗相关不良反应(AE;所有等级)是花粉尿(41.3%)。最常见的晚期不良反应(所有等级)是尿失禁(15.2%)。3-4 级急性或晚期放疗相关 AE 极少见。最常见的与放疗无关的不良反应是潮热(76%)、高血压(63%)和肝细胞溶解(50%,其中20%为3-4级)。11%的患者CTC计数≥5,这与较差的bRFS(p = 0.042)和alt-bRFS(p = 0.008)相关。CTC 计数与较高的复发率之间的关系与基线 PSA 水平和 PSA 倍增时间无关(分别为 p = 0.42 和 p = 0.09)。本研究为非随机研究,患者人数有限,报告的临床事件很少:结论:在挽救性放疗和戈舍瑞林的基础上加用 AAP 可获得较高的 bRFS 和 alt-bRFS。尽管建议对肝脏进行密切监测,但AEs仍在可控范围内。患者总结:我们的研究是一项二期临床试验,它显示了一种新型雄激素受体靶向药物(醋酸阿比特龙加泼尼松)在前列腺癌根治术后前列腺特异性抗原升高的前列腺癌患者中的疗效和耐受性,并结合了前列腺床放疗。研究结果还显示了循环肿瘤细胞检测的可行性和潜在价值,这可能是治疗前列腺癌的一大进步。
{"title":"Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial.","authors":"Loic Ah-Thiane, Loic Campion, Nedjla Allouache, Emmanuel Meyer, Pascal Pommier, Nathalie Mesgouez-Nebout, Anne-Agathe Serre, Gilles Créhange, Valentine Guimas, Emmanuel Rio, Paul Sargos, Sylvain Ladoire, Céline Mahier Ait Oukhatar, Stéphane Supiot","doi":"10.1016/j.euo.2024.04.014","DOIUrl":"https://doi.org/10.1016/j.euo.2024.04.014","url":null,"abstract":"<p><strong>Background: </strong>The relevance of next-generation hormone therapies and circulating tumor cells (CTCs) are not elucidated in biochemical recurrence after prostatectomy.</p><p><strong>Objective: </strong>To evaluate the combination of abiraterone acetate plus prednisone (AAP), prostate bed radiotherapy (PBRT), and goserelin in biochemically relapsing men after prostatectomy, and to investigate the utility of CTCs.</p><p><strong>Design, setting, and participants: </strong>In this single-arm multicenter phase 2 trial, 46 biochemically relapsing men were enrolled between December 2012 and January 2019. The median follow-up was 47 mo.</p><p><strong>Intervention: </strong>All patients received AAP 1000 mg daily (but 750 mg during PBRT), salvage PBRT, and goserelin.</p><p><strong>Outcome measurements and statistical analysis: </strong>The primary outcome was 3-yr biochemical recurrence-free survival (bRFS) when prostate-specific antigen (PSA) levels were ≥0.2 ng/ml. The secondary outcomes included alternative bRFS (alt-bRFS) when PSA levels were ≥0.5 ng/ml and safety assessment. CTC count was assessed.</p><p><strong>Results and limitations: </strong>The 3-yr bRFS and alt-bRFS were 81.5% (95% confidence interval or CI [66.4-90.3%]) and 95.6% (95% CI [83.5-98.9%]), respectively. The most common acute radiotherapy-related adverse effect (AE; all grades was pollakiuria (41.3%). The most common late AE (all grades) was urinary incontinence (15.2%). Grade 3-4 acute or late radiotherapy-related AEs were scarce. Most frequent AEs nonrelated to radiotherapy were hot flashes (76%), hypertension (63%), and hepatic cytolysis (50%, of which 20% were of grades 3-4). Of the patients, 11% had a CTC count of ≥5, which was correlated with poorer bRFS (p = 0.042) and alt-bRFS (p = 0.008). The association between CTC count and higher rates of relapse was independent of the baseline PSA level and PSA doubling time (p = 0.42 and p = 0.09, respectively). This study was nonrandomized with a limited number of patients, and few clinical events were reported.</p><p><strong>Conclusions: </strong>Adding AAP to salvage radiation therapy and goserelin resulted in high bRFS and alt-bRFS. AEs remained manageable, although a close liver surveillance is advised. CTC count appears as a promising biomarker for prognosis and predicting response to treatment.</p><p><strong>Patient summary: </strong>Our study was a phase 2 clinical trial that exhibited the efficacy and tolerance of a novel androgen-receptor targeting agent (abiraterone acetate plus prednisone) in patients with prostate cancer who experienced rising prostate-specific antigen after radical prostatectomy, in combination with prostate bed radiotherapy. The results also indicated the feasibility and potential value of circulating tumor cell detection, which constitutes a possible advance in managing prostate cancers.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140907917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European urology oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1